p53 Prophylactic Therapy for Cancer Prevention
Cancer Resilient Elephants The tumor suppressor Tp53 is the most mutated gene in cancers. Germ-line variations in Tp53 lead to
New 2025 AACR Screening Guidelines for Li‑Fraumeni Syndrome Now Available
The 2025 updated screening recommendations for individuals with Li-Fraumeni syndrome (LFS) are now available from the American Association for Cancer Research (AACR),
Optimizing shared decision-making for risk-reducing mastectomy in women with Li–Fraumeni syndrome using patient-reported outcome measures
Li-Fraumeni syndrome (LFS) researchers in Brazil studied factors in determining quality of life issues for women living with LFS who consider risk-reducing
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome
High resolution clustering of TP53 variants into functional classes correlates with cancer risk among germline variant carriers and identifies different
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome (“Toronto Protocol”)
In October 2016, the American Association for Cancer Research organized a meeting with international experts on Li-Fraumeni Syndrome (LFS) to
Liquid Biopsy for Li-Fraumeni Syndrome Cancer Screening: Survey Study
We invite you to participate in a survey about your experiences receiving cancer screening for Li-Fraumeni Syndrome (LFS), and your
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome
Immunotherapy has revolutionized the treatment of cancers in the last 15 years, demonstrating that a patient's very own immune system
Lesko-Fleming Empowerment Grants
Through the tremendous generosity of the Lesko and Fleming families, a newly established annual grant program will provide support for two youth personally
p53 Prophylactic Therapy for Cancer Prevention
Cancer Resilient Elephants The tumor suppressor Tp53 is the most mutated gene in cancers. Germ-line variations
New 2025 AACR Screening Guidelines for Li‑Fraumeni Syndrome Now Available
The 2025 updated screening recommendations for individuals with Li-Fraumeni syndrome (LFS) are now available from the American Association
Optimizing shared decision-making for risk-reducing mastectomy in women with Li–Fraumeni syndrome using patient-reported outcome measures
Li-Fraumeni syndrome (LFS) researchers in Brazil studied factors in determining quality of life issues for women living with
Larry Ingrassia – A difficult and inspiring journey of discovery
Lawrence Ingrassia, author of A Fatal Inheritance: How a Family Misfortune Revealed a Deadly Medical Mystery, talks about the two-decades long journey by Dr.
Raissa
I discovered the diagnosis before cancer. I had cancer twice, first in 2018 with a retroperitoneal leiomyosarcoma and in 2021 with HER2-positive and hormone-positive breast
Silvia
I discovered the syndrome in 2018 after breast cancer. My breast surgeon, after reviewing my medical history, suggested I see a geneticist, and that's how
Marina
My name is Marina, I am 43 years old and I discovered I have the syndrome in 2019 after my mother's passing at the age
Barbara
I discovered the syndrome in January 2021, after my uncle underwent genetic testing in an attempt to find a better treatment for the cancer he
Isabel
I discovered Li-Fraumeni syndrome in 2017, after breast cancer at the age of 20. The oncologist requested genetic testing, and I was fortunate to
